• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Serum PD-1 levels measured by ELISA using Nivolumab increased in advanced RCC patients: novel approach to develop companion diagnostics for antibody therapy.

作者信息

Mizutani Kosuke, Horie Kengo, Kato Taku, Nakane Keita, Kawakami Kyojiro, Fujita Yasunori, Ito Masafumi

机构信息

Department of Urology, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu, Gifu, 501-1194, Japan.

Research Team for Mechanism of Aging, Tokyo Metropolitan Institute of Gerontology, 35-2 Sakae-cho, Itabashi-ku, Tokyo, 173-0015, Japan.

出版信息

J Cancer Res Clin Oncol. 2019 Jun;145(6):1661-1663. doi: 10.1007/s00432-018-2806-2. Epub 2018 Dec 5.

DOI:10.1007/s00432-018-2806-2
PMID:30515569
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6527537/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2934/11810331/6ef3da79e5c0/432_2018_2806_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2934/11810331/6ef3da79e5c0/432_2018_2806_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2934/11810331/6ef3da79e5c0/432_2018_2806_Fig1_HTML.jpg

相似文献

1
Serum PD-1 levels measured by ELISA using Nivolumab increased in advanced RCC patients: novel approach to develop companion diagnostics for antibody therapy.使用纳武单抗通过酶联免疫吸附测定法检测的晚期肾细胞癌患者血清中程序性死亡受体1（PD-1）水平升高：开发抗体治疗伴随诊断的新方法。
J Cancer Res Clin Oncol. 2019 Jun;145(6):1661-1663. doi: 10.1007/s00432-018-2806-2. Epub 2018 Dec 5.
2
Metastatic Renal Medullary Carcinoma Treated With Immune Checkpoint Inhibitor: Case Report and Literature Review.免疫检查点抑制剂治疗转移性肾髓质癌：病例报告及文献综述
Clin Genitourin Cancer. 2018 Dec;16(6):e1087-e1090. doi: 10.1016/j.clgc.2018.07.011. Epub 2018 Jul 21.
3
Complete and Prolonged Response of Renal Cell Carcinoma With Rhabdoid Features to Checkpoint Inhibitor Therapy.肾细胞癌伴横纹肌样特征的完全和持久缓解对检查点抑制剂治疗的反应。
J Immunother. 2018 Sep;41(7):340-342. doi: 10.1097/CJI.0000000000000238.
4
Emerging immunotherapy in advanced renal cell carcinoma.晚期肾细胞癌中的新兴免疫疗法。
Urol Oncol. 2017 Dec;35(12):687-693. doi: 10.1016/j.urolonc.2017.08.011. Epub 2017 Sep 8.
5
Pathologic response and surgical outcomes in patients undergoing nephrectomy following receipt of immune checkpoint inhibitors for renal cell carcinoma.接受免疫检查点抑制剂治疗后行肾切除术的肾细胞癌患者的病理反应和手术结果
Urol Oncol. 2019 Dec;37(12):924-931. doi: 10.1016/j.urolonc.2019.08.012. Epub 2019 Sep 12.
6
Nivolumab-induced hepatitis: A rare side effect of an immune check point inhibitor.纳武单抗诱发的肝炎：一种免疫检查点抑制剂的罕见副作用。
J Oncol Pharm Pract. 2020 Mar;26(2):459-461. doi: 10.1177/1078155219837342. Epub 2019 Mar 25.
7
Check point inhibitors a new era in renal cell carcinoma treatment.检查点抑制剂：肾癌治疗的新时代。
Med Oncol. 2018 May 4;35(6):85. doi: 10.1007/s12032-018-1147-y.
8
Nivolumab for the treatment of hepatocellular carcinoma.纳武利尤单抗治疗肝细胞癌。
Expert Opin Biol Ther. 2020 Jul;20(7):687-693. doi: 10.1080/14712598.2020.1749593. Epub 2020 Apr 20.
9
Clinical decision-making for immunotherapy in metastatic renal cell carcinoma.转移性肾细胞癌免疫治疗的临床决策
Curr Opin Urol. 2018 Jan;28(1):29-34. doi: 10.1097/MOU.0000000000000456.
10
Percutaneous ablative cryoimmunotherapy for micrometastaic abscopal effect: No complications.经皮消融冷冻免疫疗法治疗微小转移灶的远隔效应：无并发症。
Cryobiology. 2018 Jun;82:22-26. doi: 10.1016/j.cryobiol.2018.04.013. Epub 2018 Apr 19.

引用本文的文献

1
EGLIF-CAR-T Cells Secreting PD-1 Blocking Antibodies Significantly Mediate the Elimination of Gastric Cancer.分泌PD-1阻断抗体的EGLIF-CAR-T细胞显著介导胃癌的消除。
Cancer Manag Res. 2020 Sep 23;12:8893-8902. doi: 10.2147/CMAR.S260915. eCollection 2020.

本文引用的文献

1
Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer.可溶性程序性死亡受体-1和程序性死亡配体-1：在癌症中的预测和预后意义
Oncotarget. 2017 May 31;8(57):97671-97682. doi: 10.18632/oncotarget.18311. eCollection 2017 Nov 14.
2
Systematic Review of Immune Checkpoint Inhibition in Urological Cancers.免疫检查点抑制剂在泌尿系统肿瘤中的系统评价
Eur Urol. 2017 Sep;72(3):411-423. doi: 10.1016/j.eururo.2017.06.012. Epub 2017 Jun 20.
3
Predictive biomarkers for checkpoint inhibitor-based immunotherapy.基于检查点抑制剂的免疫疗法的预测性生物标志物。
Lancet Oncol. 2016 Dec;17(12):e542-e551. doi: 10.1016/S1470-2045(16)30406-5.
4
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.纳武单抗与依维莫司治疗晚期肾细胞癌的比较
N Engl J Med. 2015 Nov 5;373(19):1803-13. doi: 10.1056/NEJMoa1510665. Epub 2015 Sep 25.
5
Development and Fit-for-Purpose Validation of a Soluble Human Programmed Death-1 Protein Assay.可溶性人程序性死亡-1蛋白检测方法的开发及适用性验证
AAPS J. 2015 Jul;17(4):976-87. doi: 10.1208/s12248-015-9762-4. Epub 2015 May 1.